Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study-Reference-Cited by-同舟云学术

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

Published:2023-10 Issue:10 Volume:11 Page:905-915
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Lu Shun,Zhou Jianying,Jian Hong,Wu Lin,Cheng Ying,Fan Yun,Fang Jian,Chen Gongyan,Zhang Zhihong,Lv Dongqing,Jiang Liyan,Wu Rong,Jin Xiangming,Zhang Xiaodong,Zhang Junhong,Xie Conghua,Sun Gengyun,Huang Dongning,Cui Jiuwei,Guo Renhua,Han Zhigang,Chen Zhendong,Liang Jin,Zhuang Wu,Hu Xingsheng,Zang Aimin,Zhang Yi,Cang Shundong,Lan Yuanbo,Chen Xi,Liu Laiyu,Li Xingya,Chen Jun,Ma Rui,Guo Yanzhen,Sun Ping,Tian Panwen,Pan Yueyin,Liu Zhe,Cao Peiguo,Ding Lieming,Wang Yang,Yuan Xiaobin,Wu Pengxiang

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference20 articles.

1. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N Engl J Med,2009

2. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007

3. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J Thorac Oncol,2014

4. Worldwide frequency of commonly detected EGFR mutations;Graham;Arch Pathol Lab Med,2018

5. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update;Hanna;J Clin Oncol,2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial;Lung Cancer;2024-09

2. Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs;Future Oncology;2024-08-19

3. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

4. “Tumor-free survival” Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC;Journal of Thoracic Oncology;2024-08

5. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches;Molecular Cancer;2024-07-25